Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen

Drugs in R and D

Volumn 17, Issue 1, 2017, Pages 177-187

  Kato, Hideo ^a   Hagihara, Mao ^a   Hirai, Jun ^a   Sakanashi, Daisuke ^a   Suematsu, Hiroyuki ^a   Nishiyama, Naoya ^a   Koizumi, Yusuke ^a   Yamagishi, Yuka ^a   Matsuura, Katsuhiko ^a   Mikamo, Hiroshige ^a  

^a AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM; CARBAPENEM; CARBAPENEM DERIVATIVE; CREATININE; QUINOLONE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BODY WEIGHT; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; ADOLESCENT; DOSE RESPONSE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MONTE CARLO METHOD; STRUCTURE ACTIVITY RELATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES; STRUCTURE-ACTIVITY RELATIONSHIP; YOUNG ADULT;

EID: 85008477475     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-016-0165-5     Document Type: Article

References (27)

1. Tally FP, Louie TJ, Weinstein WM, Bartlett JG, Gorbach SL. Amikacin therapy for severe Gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms. Ann Intern Med. 1975;83:484–8.
2. Zelenitsky SA, Harding GK, Sun S, Ubhi K, Ariano RE. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003;52:668–74.
3. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001;52(Suppl 1):35S–43S.
4. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther. 1997;21:362–9.
5. Demczar DJ, Nafziger AN, Bertino JS Jr. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Anitimicrob Agents Chemother. 1977;41:1115–9.
6. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93–9.
7. Kashuba AD, Nafziger AN, Drusano GL, Bertio JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43(3):623–9.
8. Burdet C, Pajot O, Couffignal C, Armand-Lefevre L, Foucrier A, Laouenan C, Wolff M, Massias L, Mentre F. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol. 2015;71:75–83.
9. Galvez R, Luengo C, Crnejo R, Kosche J, Romero C, Tobar E, Illanes V, Llanos O, Castro J. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents. 2011;38:146–51.
10. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; Twenty-Third informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
12. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean body weight. Clin Pharmacokinet. 2005;44:1051–65.
13. Sherwin CM, Kiang TK, Spigarelli MG, Ensom MH. Fundamentals of population pharmacokinetic modelling: validation methods. Clin Pharmacokinet. 2012;51:573–90.
14. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37(6):486–95.
15. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001;52(Suppl 1):35S–43S.
16. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther. 1977;21(3):362–9.
17. Demczar DJ, Nafziger AN, Bertino JS Jr. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother. 1997;41(5):1115–9.
18. European committee on antimicrobial susceptibility testing. MIC distribution for a wide range of organisms and antimicrobial agents, including antifungals, version 5.16b. 2007.
19. Khan MA, Faiz A. Antimicrobial resistance patterns of Pseudomonas aeruginosa in tertiary care hospitals of Makkah and Jeddah. Ann Saudi Med. 2016;36:23–8.
20. Craig WA. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother. 1995;7(Suppl. 2):47–52.
21. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, Langenaeken J, Paesmans M, Viscoli C, Glauser MP. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The international antimicrobial therapy cooperative group og the European organization for research and treatment of cancer. Antimicrob Agents Chemother. 1995;39:445–52.
22. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med. 1993;119:584–93.
23. Yu T, Stockmann C, Healy DP, Olson J, Wead S, Neely AN, Kagan RJ, Spigarelli MG, Sherwin CM. Determination of optimal amikacin dosing regimens for pediatric patients with burn wound sepsis. J Burn Care Res. 2015;36:244–52.
24. Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci. 2013;17:285–91.
25. Tod M, Lortholary O, Seytre D, Semaoun R, Uzzan B, Guillevin L, Casassus P, Petitjean O. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. 1998;42:849–56.
26. Zahar JR, Timsit JF, Garrouste-Orgeas M, Francais A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, Allaluchiche B, Azoulay E, Adrie C. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
27. Hagihara M, Kato H, Hamada Y, Hirai J, Sakanashi D, Sematsu H, Nishiyama N, Koizumi Y, Yamagishi Y, Matsuura K, Mikamo H. Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens. 2016;22:436–43.